Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MTBVAC in Healthy Adults
NCT02013245Phase 1Completed
- Sponsor
- Biofabri
- Start
- Jan 2013
- Primary completion
- Jun 2014
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mtbvac in Tuberculosis (TB) (4 arms), sponsored by Biofabri. Primary endpoint: Number of Participants With Adverse Events at 210 days. Started Jan 2013; status: completed.
02
Drugs
mtbvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02013245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013245.